General Surgery, Department of Surgery, Montefiore Medical Center, The Bronx, NY, USA.
Section of Endocrine Surgery, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
World J Surg. 2021 May;45(5):1475-1482. doi: 10.1007/s00268-021-05967-y. Epub 2021 Feb 7.
Outcomes after adrenalectomy in patients with primary aldosteronism (PA) are variable. The aldosteronoma resolution score (ARS) uses preoperative variables to calculate a score that identifies those patients that are more likely to have resolution of hypertension after adrenalectomy. We aim to determine the efficacy of adrenalectomy and whether the ARS accurately predicts clinical success in a Black and Hispanic population.
We reviewed patients who underwent adrenalectomy for PA from 2004 to 2018 at two academic centers treating primarily Hispanic and Black patients. Postoperative outcomes were evaluated based on the primary aldosteronism surgical outcome consensus criterion. Retrospectively, the accuracy of ARS was determined by a receiver operating characteristic curve and the area under the curve (AUC).
Forty-three Hispanic and 10 Black patients underwent adrenalectomy for PA. Twenty-two patients (41.5%) had complete clinical success. Variables associated with complete clinical success in the univariate analysis were female gender (p = 0.026), younger age (p = 0.001), lower preoperative aldosterone (p = 0.035), lower preoperative systolic blood pressure (p = 0.001), fewer number of preoperative antihypertensive medications (p = 0.007) and a higher ARS (p = 0.003). On multivariate analysis, only fewer number of preoperative antihypertensive medications was independently associated with complete clinical success (p = 0.026). The AUC of the ARS was 0.746.
The rate of clinical success from adrenalectomy is good for Hispanic and Black patients with PA. Our analysis shows that the ARS is an accurate test of clinical success in Hispanic and Black patients. The ARS may be utilized preoperatively to frame expectations after adrenalectomy in these populations.
醛固酮增多症(PA)患者肾上腺切除术的结果各不相同。醛固酮瘤缓解评分(ARS)使用术前变量来计算一个评分,该评分可识别出那些术后高血压更有可能得到缓解的患者。我们旨在确定肾上腺切除术的疗效,以及 ARS 是否能准确预测黑人和西班牙裔人群的临床成功。
我们回顾了 2004 年至 2018 年在两家主要治疗西班牙裔和黑人患者的学术中心接受肾上腺切除术治疗 PA 的患者。根据原发性醛固酮增多症手术结果共识标准评估术后结果。通过受试者工作特征曲线和曲线下面积(AUC)来确定 ARS 的准确性。
43 名西班牙裔和 10 名黑人患者因 PA 接受了肾上腺切除术。22 名患者(41.5%)完全临床治愈。单因素分析中与完全临床治愈相关的变量包括女性(p=0.026)、年龄较小(p=0.001)、术前醛固酮较低(p=0.035)、术前收缩压较低(p=0.001)、术前降压药种类较少(p=0.007)和 ARS 较高(p=0.003)。多因素分析显示,只有术前降压药种类较少与完全临床治愈独立相关(p=0.026)。ARS 的 AUC 为 0.746。
对于患有 PA 的西班牙裔和黑人患者,肾上腺切除术的临床治愈率较高。我们的分析表明,ARS 是西班牙裔和黑人患者临床成功的准确测试。ARS 可在术前用于预测这些人群肾上腺切除术后的效果。